Literature DB >> 29928367

Quantitative proteomic analysis of the miR-148a-associated mechanisms of metastasis in non-small cell lung cancer.

Dandan Chu1, Jing Li1, Hechun Lin1, Xiao Zhang1, Hongyu Pan1, Lei Liu1, Tao Yu1, Mingxia Yan1, Ming Yao1.   

Abstract

MicroRNAs (miRs) are small non-coding RNAs that regulate gene expression and protein synthesis. Our previous study demonstrated that miR-148a suppressed the metastasis of non-small cell lung cancer (NSCLC) in vitro and in vivo. However, the modulatory mechanism of this effect remains unclear. In the present study, quantitative proteomic technology was used to study the protein expression profile of SPC-A-1 cells subsequent to the downregulation of miR-148a expression, in order to elucidate the molecular mechanism of the suppression of NSCLC metastasis by miR-148a. The differentially expressed proteins identified were analyzed using bioinformatics tools, including the Database for Annotation, Visualization and Integrated Discovery and the Search Tool for the Retrieval of Interacting Genes/proteins. In two experiments, 4,048 and 4,083 proteins were identified, and 4,014 and 4,039 proteins were quantified, respectively. In total, 44 proteins were upregulated and 40 proteins were downregulated. This was verified at the protein and mRNA levels by western blotting and reverse transcription-quantitative polymerase chain reaction, respectively. Bioinformatics analysis was used to identify potential interactions and signaling networks for the differentially expressed proteins. This may have provided an appropriate perspective for the comprehensive analysis of the modulatory mechanism underlying the metastasis-suppressive effects of miR-148a in NSCLC. In conclusion, quantitative proteomic technology revealed that miR-148a may regulate a panel of tumor-associated proteins to suppress metastasis in NSCLC.

Entities:  

Keywords:  bioinformatics analysis; metastasis; microRNA-148a; non-small cell lung cancer; proteomic

Year:  2018        PMID: 29928367      PMCID: PMC6004687          DOI: 10.3892/ol.2018.8581

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  66 in total

1.  MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer.

Authors:  Akao Zhu; Jiazeng Xia; Junbo Zuo; Shimao Jin; Hong Zhou; Lubin Yao; Hongyu Huang; Zhijun Han
Journal:  Med Oncol       Date:  2011-12-14       Impact factor: 3.064

2.  Increased fatty acid synthase activity in non-small cell lung cancer tissue is a weaker predictor of shorter patient survival than increased lipoprotein lipase activity.

Authors:  Darko Cerne; Irena Prodan Zitnik; Miha Sok
Journal:  Arch Med Res       Date:  2010-08       Impact factor: 2.235

Review 3.  Role of laminins in physiological and pathological angiogenesis.

Authors:  Patricia Simon-Assmann; Gertraud Orend; Elmina Mammadova-Bach; Caroline Spenlé; Olivier Lefebvre
Journal:  Int J Dev Biol       Date:  2011       Impact factor: 2.203

4.  miR-134 suppresses the migration and invasion of non‑small cell lung cancer by targeting ITGB1.

Authors:  Qin Qin; Furong Wei; Jianbo Zhang; Baosheng Li
Journal:  Oncol Rep       Date:  2017-01-03       Impact factor: 3.906

Review 5.  MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis.

Authors:  Keiko Mizuno; Hiroko Mataki; Naohiko Seki; Tomohiro Kumamoto; Kazuto Kamikawaji; Hiromasa Inoue
Journal:  J Hum Genet       Date:  2016-08-04       Impact factor: 3.172

6.  Cancer statistics for Hispanics/Latinos, 2015.

Authors:  Rebecca L Siegel; Stacey A Fedewa; Kimberly D Miller; Ann Goding-Sauer; Paulo S Pinheiro; Dinorah Martinez-Tyson; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-09-16       Impact factor: 508.702

7.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.

Authors:  Ian P M Tomlinson; N Afrina Alam; Andrew J Rowan; Ella Barclay; Emma E M Jaeger; David Kelsell; Irene Leigh; Patricia Gorman; Hanan Lamlum; Shamima Rahman; Rebecca R Roylance; Simon Olpin; Stephen Bevan; Karen Barker; Nicholas Hearle; Richard S Houlston; Maija Kiuru; Rainer Lehtonen; Auli Karhu; Susa Vilkki; Päivi Laiho; Carita Eklund; Outi Vierimaa; Kristiina Aittomäki; Marja Hietala; Pertti Sistonen; Anders Paetau; Reijo Salovaara; Riitta Herva; Virpi Launonen; Lauri A Aaltonen
Journal:  Nat Genet       Date:  2002-02-25       Impact factor: 38.330

8.  α-actinin-4 is essential for maintaining the spreading, motility and contractility of fibroblasts.

Authors:  Hanshuang Shao; James H-C Wang; Martin R Pollak; Alan Wells
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

Review 9.  The role of endothelial-to-mesenchymal transition in cancer progression.

Authors:  S Potenta; E Zeisberg; R Kalluri
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

10.  Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling.

Authors:  J Li; H Wu; W Li; L Yin; S Guo; X Xu; Y Ouyang; Z Zhao; S Liu; Y Tian; Z Tian; J Ju; B Ni; H Wang
Journal:  Oncogene       Date:  2016-04-11       Impact factor: 9.867

View more
  3 in total

1.  Identification of an 8-miRNA signature as a potential prognostic biomarker for glioma.

Authors:  Baowei Ji; Lihua Chen; Qiang Cai; Qiao Guo; Zhibiao Chen; Du He
Journal:  PeerJ       Date:  2020-09-28       Impact factor: 2.984

2.  MiR-148a inhibits oral squamous cell carcinoma progression through ERK/MAPK pathway via targeting IGF-IR.

Authors:  Tingting Jia; Yipeng Ren; Fengze Wang; Rui Zhao; Bo Qiao; Lejun Xing; Long Ou; Bin Guo
Journal:  Biosci Rep       Date:  2020-04-30       Impact factor: 3.840

3.  A network-based approach to uncover microRNA-mediated disease comorbidities and potential pathobiological implications.

Authors:  Shuting Jin; Xiangxiang Zeng; Jiansong Fang; Jiawei Lin; Stephen Y Chan; Serpil C Erzurum; Feixiong Cheng
Journal:  NPJ Syst Biol Appl       Date:  2019-11-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.